Hemophilia, a rare genetic blood disorder that impairs the ability of blood to clot, is the cornerstone of the Rare Blood Disorders franchise. Our extended half-life factor replacement therapies for people with hemophilia A and B were launched in 2014, becoming the first innovations in hemophilia management in 20 years. We launched the first approved treatment for acquired thrombotic thrombocytopenic purpura (aTTP), a rare, life-threatening, autoimmune-based blood disorder.
To gain an appreciation and understanding of the role of the US Medical and Global Scientific Engagement & Communications team in Rare Blood Disorders, through broad hands-on experiences, dedicated mentorship, and longitudinal core responsibilities.
Become an integral part of the Global Rare Blood Disorders team in developing and executing medical brand strategies and tactics within the framework of the business unit.
Collaborate with key internal and external stakeholders and scientific communications agencies, providing writing, editorial, and/or project management support in accordance with policies and International Committee of Medical Journal Editors (ICMJE) guidelines.
Contribute to the execution of the strategic medical communication tactics including scientific education and training materials, interactive digital materials, and resources to support the field medical team.
Understand the integral and strategic roles of various functional groups within Rare Blood Disorders and across Sanofi through a drug’s lifecycle.
Work cross-functionally to ensure that activities and initiatives are strategically aligned and maintain the highest standards of compliance in accordance with corporate policies and all regulations.
To be considered for an interview, please complete a fellowship application on the MCPHS SMApply application portal. Visit https://mcphs.smapply.io/
Please DO NOT request an interview within PPS. Our recruitment teams will contact qualified candidates via email to schedule interviews.
The MCPHS application portal will open up on October 2, 2023. Applicants must upload the following application materials to the online portal by November 17, 2023:
Letter of intent
Unofficial college transcript
Contact information for three references. References will receive an electronic recommendation form to complete separately.
Incomplete applications WILL NOT be reviewed. Interviews CANNOT be scheduled until these materials have been submitted. Please keep in mind that this is a competitive process and applicants are encouraged to complete their applications as soon as possible.
Three recommendation evaluation forms must be submitted no later than November 27, 2023, via the online portal. This is NOT a letter of recommendation but an online form that the reference will need to complete.
Rolling Application Review & Interviews
All submitted applications will be reviewed on a rolling basis. Interviews will also be offered on a rolling basis and opportunities are limited. Priority will be given to those applicants who apply early, well in advance of the deadline.
Rolling interviews will begin mid-October with pre-screens and a mixture of interview rounds, and will conclude in December at the end of the ASHP Midyear Clinical Meeting. Candidates will be notified if selected for an interview.
ASHP Midyear & Onsite Interviews
The fellowship program will be conducting in-person interviews at the ASHP Midyear Clinical Meeting in Burbank, CA. Applicants are strongly encouraged to attend. Candidates attending in-person will not be able to interview without registering for both ASHP and PPS. Please refer to the ASHP & PPS website for registration details.
Top candidates may be invited for interviews at the sponsoring company’s location pending COVID – 19 restrictions.
Recognizing that the choice of a Post-Doctoral Industry Fellowship is an important decision, MCPHS in conjunction with the Academic Industry Fellowship Alliance (AIFA), has agreed to extend offers for Fellowships no earlier than December 13, 2023.
Final candidates will be required to go through additional screening / onboarding as required by MCPHS.
The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis. Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program.
Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
All candidates must have authorization to work in the United States throughout the duration of the one or two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.).
Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Sanofi’s global specialty care business unit focuses on rare diseases, rare blood disorders, neurology, immunology, and oncology. Its approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Our cutting-edge science and manufacturing, fueled by data and digital technologies, have the potential to transform the practice of medicine for millions of people around the world.